| __timestamp | Alkermes plc | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 79838000 |
| Thursday, January 1, 2015 | 483393000 | 121816000 |
| Friday, January 1, 2016 | 519270000 | 117633000 |
| Sunday, January 1, 2017 | 567637000 | 4577000 |
| Monday, January 1, 2018 | 601826000 | 12670000 |
| Tuesday, January 1, 2019 | 693218000 | 12135000 |
| Wednesday, January 1, 2020 | 572904000 | 18942000 |
| Friday, January 1, 2021 | 603913000 | 32328000 |
| Saturday, January 1, 2022 | 218108000 | 44678000 |
| Sunday, January 1, 2023 | 253037000 | 65486000 |
| Monday, January 1, 2024 | 245331000 |
In pursuit of knowledge
In the competitive landscape of biopharmaceuticals, understanding cost structures is crucial. Alkermes plc and PTC Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Alkermes, with a peak cost of revenue in 2019, saw a significant decline of approximately 64% by 2022. In contrast, PTC Therapeutics, starting with a modest cost in 2014, experienced a steady increase, reaching a high in 2023, marking an impressive growth of over 700% from its 2017 low. This divergence highlights strategic differences in operational efficiency and market positioning. As the industry evolves, these insights offer a glimpse into how companies adapt to challenges and opportunities, shaping their financial narratives.
Novo Nordisk A/S vs Alkermes plc: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Biogen Inc. vs PTC Therapeutics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Exelixis, Inc. and PTC Therapeutics, Inc.
Alkermes plc vs Veracyte, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and ACADIA Pharmaceuticals Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and MiMedx Group, Inc.